ClinicalTrials.gg
CompletedNCT00419094Updated Sep 5, 2014Results posted

Conversion to Monotherapy Study With Keppra XR for Partial Seizures

A Phase 3 interventional study of Keppra XR and Keppra XR in Epilepsy, sponsored by UCB Pharma. Completed at 46 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-05.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
14th of 60
228 · median 94
Started
2007
with 6 others
Phase 3
28 of 60
2 open now
Registered
19th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 14th largest by enrollment, is one of 7 that started in 2007, is one of 28 in phase 3, and was the 19th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.

03

Conditions studied

  • Epilepsy

Keywords

  • Keppra XR
  • conversion to monotherapy
  • partial seizures
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 12 to 75 years of age.
  • Subjects must have inadequately controlled partial onset epilepsy.
  • Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s)

Exclusion criteria

Exclusion Criteria:

  • A history of status epilepticus in the 6 months preceding randomization.
  • Significant medical, psychiatric or neurological illness.
  • Intake of benzodiazepines on more than an occasional basis
  • History of previous treatment with levetiracetam or sensitivity to levetiracetam.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Keppra XR 1000 mg/day

    1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)

    Drug: Keppra XR

  • Experimental
    Keppra XR 2000 mg/day

    2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)

    Drug: Keppra XR

Interventions

  • Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks

  • Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks

06

What researchers measure

Primary outcomes

  1. The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase

    Cumulative exit rate at day 112, based on the duration between start date of previous AED tapering to the earliest date exit criterion was met; calculated using Kaplan Meier Methods. Subjects prematurely discontinued for reasons unrelated to exit criteria were censored as of last dose of study drug. Subjects who completed without meeting exit criteria were censored at Day 112. Exit criteria include increase in seizure frequency, severity, duration, status epilepticus, or new generalized seizure. Upper 95% 2-sided confidence limit for exit rate is compared to the historical control rate: 0.678.

    Time frame: 112 days

Secondary outcomes

  1. The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase

    The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who prematurely discontinued for reasons unrelated to exit criteria, adverse event, or lack of efficacy were censored as of the last dose of study medication. Subjects who completed the study without having an exit event were censored as of Day 112.

    Time frame: 112 days

  2. The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase

    The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who completed the study without having an exit event were censored as of Day 112.

    Time frame: 112 days

  3. The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase

    Keppra XR 1000 mg arm was not intended for inferential analysis (planned 3 to 1 randomization, Keppra XR 2000 mg: 1000 mg). The Exit Rate was based on the duration between the start date of previous AED tapering to the earliest date an exit crterion was met. Subjects who prematurely discontinued for reasons unrelated to exit criteria were censored as of the last dose of study medication. Subjects who completed the study without meeting an exit criterion were censored as of Day 112.

    Time frame: 112 days

07

Results

Posted Dec 20, 2010

Participant flow

The Efficacy (EFF) population is defined as all subjects in the Intent to Treat (ITT) population who enter into the Previous Antiepileptic (AED) Discontinuation (D/C) Phase. The Per Protocol (PP) population consists of all subjects in the EFF population who have no important protocol deviations related to efficacy.

Participant flow — Overall Study
MilestoneKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
Started57171
Completed50141
Not completed730
Withdrew: Adverse event37
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up02
Withdrew: Protocol violation114
Withdrew: Withdrawal of consent15
Withdrew: Other: error determining exit criteria10
Withdrew: Other: patient non-compliant01
Withdrew: Other: no contact for extended period01

Outcome measures

PrimaryThe Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase

Cumulative exit rate at day 112, based on the duration between start date of previous AED tapering to the earliest date exit criterion was met; calculated using Kaplan Meier Methods. Subjects prematurely discontinued for reasons unrelated to exit criteria were censored as of last dose of study drug. Subjects who completed without meeting exit criteria were censored at Day 112. Exit criteria include increase in seizure frequency, severity, duration, status epilepticus, or new generalized seizure. Upper 95% 2-sided confidence limit for exit rate is compared to the historical control rate: 0.678.

Time frame:
112 days
Reported as:
Number · proportion of subjects
The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase
proportion of subjectsKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase—0.375 (0.297 to 0.453)
SecondaryThe Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase

The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who prematurely discontinued for reasons unrelated to exit criteria, adverse event, or lack of efficacy were censored as of the last dose of study medication. Subjects who completed the study without having an exit event were censored as of Day 112.

Time frame:
112 days
Reported as:
Number · proportion of subjects
The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase
proportion of subjectsKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase—0.385 (0.307 to 0.463)
SecondaryThe Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase

The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who completed the study without having an exit event were censored as of Day 112.

Time frame:
112 days
Reported as:
Number · proportion of subjects
The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase
proportion of subjectsKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase—0.475 (0.397 to 0.553)
SecondaryThe Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase

Keppra XR 1000 mg arm was not intended for inferential analysis (planned 3 to 1 randomization, Keppra XR 2000 mg: 1000 mg). The Exit Rate was based on the duration between the start date of previous AED tapering to the earliest date an exit crterion was met. Subjects who prematurely discontinued for reasons unrelated to exit criteria were censored as of the last dose of study medication. Subjects who completed the study without meeting an exit criterion were censored as of Day 112.

Time frame:
112 days
Reported as:
Number · proportion of subjects
The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase
proportion of subjectsKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase0.334 (0.204 to 0.465)—

Adverse events

Collected over Up to 29 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Keppra XR 1000 mg/Day—2/57 (3.5%)33/57 (57.9%)
Keppra XR 2000 mg/Day—12/171 (7%)87/171 (50.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
convulsionNervous system disorders1/574/171
acute psychosisPsychiatric disorders1/570/171
haemorrhoidal haemorrhageGastrointestinal disorders0/571/171
pancreatitis acuteGastrointestinal disorders0/571/171
pulmonary tuberculosisInfections and infestations0/571/171
pyelonephritisInfections and infestations0/571/171
ankle fractureInjury, poisoning and procedural complications0/571/171
back painMusculoskeletal and connective tissue disorders0/571/171
intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/571/171
lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/571/171
Most frequent other events
Most frequent other events
EventKeppra XR 1000 mg/DayKeppra XR 2000 mg/Day
headacheNervous system disorders13/5732/171
somnolenceNervous system disorders12/5738/171
convulsionNervous system disorders9/5720/171
dizzinessNervous system disorders3/5715/171
irritablilityGeneral disorders3/5712/171
vertigoEar and labyrinth disorders3/577/171
abdominal painGastrointestinal disorders3/576/171
nasopharyngitisInfections and infestations3/577/171

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Keppra XR 1000 mg/DayKeppra XR 2000 mg/DayTotal
<=18 years113142
Between 18 and 65 years43140183
>=65 years303
Age, Continuous
Age, Continuous(years)Keppra XR 1000 mg/DayKeppra XR 2000 mg/DayTotal
Mean33.48 ± 16.3234.31 ± 13.6934.11 ± 14.36
Sex: Female, Male
Sex: Female, Male(Participants)Keppra XR 1000 mg/DayKeppra XR 2000 mg/DayTotal
Female3399132
Male247296
Region of Enrollment
Region of Enrollment(participants)Keppra XR 1000 mg/DayKeppra XR 2000 mg/DayTotal
United States82937
Mexico174360
Poland165167
Russian Federation164864
08

Study locations

46 sites
  • Dothan, Alabama, United States
  • Northport, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Bakersfield, California, United States
  • Jacksonville, Florida, United States
  • Loxahatchee, Florida, United States
  • Atlanta, Georgia, United States
  • Suwanee, Georgia, United States
  • Winfield, Illinois, United States
  • Witchita, Kansas, United States
  • Shreveport, Louisiana, United States
  • Bethesda, Maryland, United States
  • Detroit, Michigan, United States
  • Camden, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Buffalo, New York, United States
  • Cedarhurst, New York, United States
  • Toledo, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Bend, Oregon, United States
  • Monaca, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Beaufort, South Carolina, United States
  • Monterrey, NL, Mexico
  • Aguascalientes, Mexico
  • Distrio federal, Mexico
  • Guadalajara Jalisco, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Monterrey, Mexico
  • Bialystok, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Kalingrad, Russian Federation
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Samara, Russian Federation
  • St Petersburg, Russian Federation
  • St. Petersburg, Russian Federation
  • Yaroslavl, Russian Federation
09

References and documents

Publications

  • Chung S, Ceja H, Gawlowicz J, Avakyan G, McShea C, Schiemann J, Lu S. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res. 2012 Aug;101(1-2):92-102. doi: 10.1016/j.eplepsyres.2012.03.007. Epub 2012 Apr 18. PubMed 22516508 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2007
First posted
Jan 8, 2007
Start
Aug 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Dec 20, 2010
Last update
Sep 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00419094
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 8, 2007
Start date
Aug 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Dec 20, 2010
Last update
Sep 5, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion